InnoStar supported UniXell’s UX-GIP001 injection in gaining FDA IND approval as the world’s first iPSC-derived allogeneic cell therapy for epilepsy, providing comprehensive GLP-compliant nonclinical safety evaluation.

InnoStar Huangshan’s new multi-purpose research complex is completed, enhancing its NHP research capabilities, supporting regional biotech development, and advancing global drug innovation.

In 2025, InnoStar saw facility expansion, lab accreditations, talent growth with 6 DABT experts, global project successes including 8 overseas license‑outs and 10+ first‑in‑class breakthroughs, strengthening its global innovation footprint.

InnoStar’s GLP-certified Ophthalmology Integrated Evaluation Platform offers end-to-end, globally compliant "efficacy-PK-toxicity" assessments for diverse ophthalmic drugs, supporting multiple disease models, routes & species to accelerate R&D.

InnoStar offers globally compliant, full-life-cycle DMPK services via its advanced non-clinical PK platform, supporting diverse drug modalities with in vitro/in vivo studies, radioactive ADME work, and aiding over 200 first-in-class projects.